Swissmedic
SAFETY ALERT
Reassessment of the safety of blood transfusions with regard to vCJD
Published: 1/13/2026Detected: 3/26/2026
Summary preview
Reassesses the risk of transmissible spongiform encephalopathy (vCJD) associated with blood transfusions and supports updating risk-management expectations for donor screening, processing, and safety controls.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from SWISSMEDIC.
More from Swissmedic
- Changes to the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”10/1/2026
- Adaptations required for issuing establishment licences and GMP certificates for manufacturers of active substances10/1/2026
- Revision of the Guidance document Authorisation Biosimilar10/1/2026
- Swissmedic Portal Release – New Features Available from 23 September 20269/24/2026
- I-SMI.TI.22e Notifications according to Article 41, MPLO9/23/2026